Introduction {#sec1-1}
============

Breast cancer is a heterogeneous disease, composed of many morphological and molecular entities. The heterogeneity reflects different clinical outcomes (Polyak, 2007). By gene expression profiling, breast cancer is classified into 5 intrinsic subtypes (Perou et al., 2000; Sølie et al., 2001). For clinicopathological practice, 5 molecular subtypes, luminal A, luminal B (HER2-), luminal B (HER2+), HER2 and triple negative (TN), are defined based on the expression of estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2), and Ki-67 (Goldhirsch et al., 2011). TN was subdivided into two subtypes, basal-like and null (Nielsen et al., 2004; Chuangsuwanich et al., 2014). It is well known that molecular subtypes are important biological markers not only for predicting prognosis but for decisions of effective treatment (Blows et al., 2010; Engstrø et al., 2013; Sung et al., 2016). Luminal types are cancers with a better prognosis in comparison to non-luminal types. Luminal breast cancer subtypes were found to predominate across racial/ethnic groups, while frequency of TN breast cancer progressively increases among white American, African-American, and Ghanaian/Africans (Amirikia et al., 2011; Huo et al., 2009; Kurian et al., 2010; Stark et al., 2010).

As with other countries, breast cancer is a leading cause of morbidity and mortality in Myanmar women (Moore, 2014). The aim of this study was to unveil the histopathological features and molecular subtypes in Myanmar breast cancer patients. We analyzed the clinicopathological characteristics and expression patterns of ER/PgR/HER2/Ki-67 using 91 female patients with breast cancer.

Materials and Methods {#sec1-2}
=====================

Study subjects {#sec2-1}
--------------

A total of 91 female patients diagnosed with breast cancer in the year 2015 were retrieved from pathology records at Myeik General Hospital (Myeik City, Myanmar) and Sakura Specialist Hospital (Yangon City, Myanmar). Clinicopathological data such as age, tumor size, lymph node and distant metastasis status were retrieved from the clinical and pathology records. All hematoxylin and eosin-stained sections were reviewed by two independent pathologists. Criteria defined by the World Health Organization (2012) were used for the histopathological diagnosis and classification of breast carcinoma. Nottingham combined histological grading system (Elston and Ellis, 1991) was used for tumor grading. American Joint Committee on Cancer staging system 8th edition was applied for tumor staging. The experimental protocol employed in this study was approved by the Ethics Committee of Okayama University (Japan) and the Ethics Review Committee of Department of Medical Research of Yangon City (Myanmar).

Immunohistochemical analysis {#sec2-2}
----------------------------

Immunohistochemistry was performed by using standardized automated techniques according to the manufacturer's protocol. Tissue sections were stained with antibodies ER (SP1), PgR (1E2), HER2 (4B5), Ki-67 (MIB-1), cytokeratin (CK) 5/6 (D5/16B4) and CK14 (LL002) using a Discovery XT autostainer with iVIEW DAB detection kit (Ventana Medical Systems, Tucson, Arizona). In case of ER/PgR, a staining \> 1% of tumor cell nuclei was considered positive (Hammond et al., 2010). HER2 was analyzed according to the American Society of Clinical Oncology and College of American Pathologists (Wolff et al., 2013). A score of 0 to 1+ was considered as negative and 3+ as positive. Specimens with score of 2+ were analyzed by HER2 dual-color in situ hybridization at Hyogo Clinical Laboratory Cooperation (Himeji City, Japan). Ki-67 labeling index was defined as the percentage of positive nuclei, in which over 500 tumor cells were counted in each case. CK5/6 and CK14 were scored positive if any (weak or strong) cytoplasmic and/or membranous staining was observed. Breast cancers were classified into 5 molecular subtypes according to the St. Gallen International Expert Consensus 2011 (Goldhirsch et al., 2011): luminal A; ER/PgR+/HER2-/Ki-67\<14%, luminal B (HER2-); ER/PgR+/HER2-/Ki-67≥14%, luminal B (HER2+); ER/PgR+/HER2+/any Ki-67 percentage, HER2; ER/PgR-/HER2+, and TN; ER/PgR-/HER2-. TN subtype was further subdivided into basal-like type (ER/PgR-/HER2- with CK5/6+ and/or CK14+) and null type (ER/PgR-/HER2-/ CK5/6-/CK14-).

Statistical analysis {#sec2-3}
--------------------

Statistical analyses were performed using SPSS software version 16.0. Fisher's exact test was used for data categorized into 2 × 2 contingency tables. The age, mitosis count and Ki-67 expression were reported using descriptive statistics and Mann Whitney U test to compare the mean of the variables. Two-sided tests were used for all analyses and p value \<0.05 was considered as significant.

Results {#sec1-3}
=======

Patient characteristics {#sec2-4}
-----------------------

Clinical data for the enrolled 91 female patients with breast cancer were shown in [Table 1](#T1){ref-type="table"}. Ages ranged from 30 to 81 years with mean age of 51.3. Tumor sizes ranged from 1.5 cm to 7.2 cm with average size of 4.0 cm. Most of the cancers (94.5%) were invasive carcinoma of no special type (NST) with high histological grade (grade II; 46.2%, grade III; 53.8%). No grade I tumor was found. There were lymph node metastases in 57.1% of patients. The numbers of patients with stage I, II, III and IV were 6 (6.6%), 50 (54.9%), 31 (34.1%) and 4 (4.4%), respectively.

###### 

Clinical Data for the Enrolled Breast Cancer Patients

  Categories                                       Number of Cases (%)
  ------------------------------------------------ ---------------------
  Age (years)                                      
   \<35                                            4 (4.4)
   35-50                                           39 (42.9)
   \>50                                            48 (52.7)
  Tumor size (cm)                                  
   ≤2.0                                            6 (6.6)
   2.1-5.0                                         61 (67.0)
   \>5.0                                           24 (26.4)
  Histological type                                
   Invasive carcinoma of no special type (NST)     86 (94.5)
   Mucinous carcinoma                              2 (2.2)
   Carcinoma with neuroendocrine differentiation   2 (2.2)
   Pleomorphic lobular carcinoma                   1 (1.1)
  Histological grade                               
   Grade I                                         0 (0.0)
   Grade II                                        42 (46.2)
   Grade III                                       49 (53.8)
  Metastatic lymph node                            
   Absent                                          39 (42.9)
   Present                                         52 (57.1)
  Staging                                          
   Stage I                                         6 (6.6)
   Stage II                                        50 (54.9)
   Stage III                                       31 (34.1)
   Stage IV                                        4 (4.4)

Molecular subtypes and immunophenotypic analyses {#sec2-5}
------------------------------------------------

ER positive, PgR positive and HER2 positive cases were 57.1%, 37.4% and 28.6%, respectively. Molecular subtypes and clinicopathological features of 91 breast cancers were shown in [Table 2](#T2){ref-type="table"}. The frequency of luminal A, a good prognostic subtype, was 11.0%. The most common subtype (39.6%) was luminal B (HER2-). Poor-prognosis subtypes, HER2 and TN subtypes, were 22.0 and 20.9%, respectively. Among TN subtypes, 11 cases (12.1%) were basal-like type (7 cases; CK5/6+ and CK14+, 4 cases; CK5/6- and CK14+) and 8 cases (8.8%) were null type. Compared to luminal A as the reference, tumors larger than 2 cm were more in HER2 subtype. TN-basal-like also tended to be larger than 2 cm although it was not statistically significant. Histological grade III (poorly differentiated) was more frequently found in non-luminal A subtypes, particularly in TN-basal-like and HER2, with more advanced stages at diagnosis (stage II, III and IV). As compared to luminal A, HER2 subtype tended to metastasize to lymph nodes, although it was not statistically significant ([Table 2](#T2){ref-type="table"}). The mean Ki-67 index of all 91 cases was 33.9% (mean ± SD, 33.9 ± 19.2) and the median score was 28% (range; 4%-90%). In the subtype analyses, the mean Ki-67 expression was increased in the following order; luminal A \< luminal B \< HER2 \< TN (null\<basal-like), which corresponded well to the increased number of mitoses ([Table 2](#T2){ref-type="table"}).

###### 

Molecular Subtypes and Clinicopathological Features of Breast Cancers

                       Luminal A    Luminal B                                 HER2                                    Triple Negative                           Total                                                                               
  -------------------- ------------ ----------------------------------------- --------------------------------------- ----------------------------------------- ----------------------------------------- ----------------------------------------- ----
  Number (%)           10 (11.0)    36 (39.6)                                 6 (6.6)                                 20 (22.0)                                 11 (12.1)                                 8 (8.8)                                   91
  Age (years)                                                                                                                                                                                                                                       
   Mean (range)        58 (42-81)   52 (32-75)                                47 (30-60)                              51 (30-74)                                49 (35-62)                                50 (37-67)                                
   p value             reference    0.158                                     0.103                                   0.134                                     0.121                                     0.142                                     
  Tumor Size                                                                                                                                                                                                                                        
   ≤2cm                3            2                                         1                                       0                                         0                                         0                                         6
   \>2cm               7            34                                        5                                       20                                        11                                        8                                         85
   p value             reference    0.061                                     1                                       0.030[\*](#t2f1){ref-type="table-fn"}     0.09                                      0.216                                     
  Histological grade                                                                                                                                                                                                                                
   Grade II            10           25                                        1                                       2                                         1                                         3                                         42
   Grade III           0            11                                        5                                       18                                        10                                        5                                         49
   p value             reference    0.088                                     0.001[\*](#t2f1){ref-type="table-fn"}   \<0.001[\*](#t2f1){ref-type="table-fn"}   \<0.001[\*](#t2f1){ref-type="table-fn"}   0.007[\*](#t2f1){ref-type="table-fn"}     
  Nodal status                                                                                                                                                                                                                                      
   negative            7            15                                        2                                       6                                         7                                         2                                         39
   positive            3            21                                        4                                       14                                        4                                         6                                         52
   p value             reference    0.159                                     0.302                                   0.056                                     1                                         0.153                                     
  Stage                                                                                                                                                                                                                                             
   Stage I             3            2                                         1                                       0                                         0                                         0                                         6
   Stage II to IV      7            34                                        5                                       20                                        11                                        8                                         85
   p value             reference    0.061                                     1                                       0.030[\*](#t2f1){ref-type="table-fn"}     0.09                                      0.216                                     
  Ki-67 expression                                                                                                                                                                                                                                  
   Mean (range)        7 (4-13)     30 (17-80)                                30 (9-54)                               40 (18-77)                                57 (26-90)                                43 (20-75)                                
   p value             reference    \<0.001[\*](#t2f1){ref-type="table-fn"}   0.003[\*](#t2f1){ref-type="table-fn"}   \<0.001[\*](#t2f1){ref-type="table-fn"}   \<0.001[\*](#t2f1){ref-type="table-fn"}   \<0.001[\*](#t2f1){ref-type="table-fn"}   
  Mitoses/10HPF                                                                                                                                                                                                                                     
   Mean (range)        12 (6-20)    27 (6-86)                                 39 (21-72)                              40 (18-93)                                77 (38-118)                               49 (18-110)                               
   p value             reference    0.002[\*](#t2f1){ref-type="table-fn"}     0.001[\*](#t2f1){ref-type="table-fn"}   \<0.001[\*](#t2f1){ref-type="table-fn"}   \<0.001[\*](#t2f1){ref-type="table-fn"}   0.001[\*](#t2f1){ref-type="table-fn"}     

statistically significant

Association between Ki-67 expression and clinicopathological features {#sec2-6}
---------------------------------------------------------------------

The Ki-67 expression was divided into 3 levels (\<14; 12.1%, 14-30; 40.7%, \>30; 47.2%) and the associations between Ki-67 expression and clinicopathological features were investigated ([Table 3](#T3){ref-type="table"}). Compared to Ki-67\<14 as the reference, tumors with increased Ki-67 expression were associated with unfavorable features such as more mitoses and higher grade. Furthermore, younger patients, larger size (\>2 cm), and higher stage were related to tumors with \>30% Ki-67 expression. Interestingly, no difference was found in nodal status. ER/PgR negative tumors showed higher Ki-67 expression, whereas Ki-67 expression was not associated with HER2 overexpression. Overall, these data indicated that Ki-67 expression was significantly accompanied by advanced and aggressive cancer.

###### 

Association between Ki-67 Expression and Clinicopathological Features

                       Ki-67 index Categories (%)   Total                     
  -------------------- ---------------------------- ------------ ------------ ----
  Age (years)                                                                 
   Mean (range)        57 (42-81)                   54 (32-75)   48 (30-75)   
   p value             reference                    0.589        0.037\*      
  Tumor size                                                                  
   ≤2cm                3                            2            1            6
   \>2cm               8                            35           42           85
   p value             reference                    0.072        0.023\*      
  Histological grade                                                          
   Grade II            10                           20           12           42
   Grade III           1                            17           31           49
   p value             reference                    0.035\*      \<0.001\*    
  Nodal Status                                                                
   positive            4                            22           26           52
   negative            7                            15           17           39
   p value             reference                    0.302        0.186        
  Stage                                                                       
   Stage I             3                            2            1            6
   Stage II to IV      8                            35           42           85
   p value             reference                    0.072        0.023\*      
  ER                                                                          
   positive            11                           26           15           52
   negative            0                            11           28           39
   p value             reference                    0.048\*      \<0.001\*    
  PgR                                                                         
   positive            11                           15           8            34
   negative            0                            22           35           57
   p value             reference                    \<0.001\*    \<0.001\*    
  HER2                                                                        
   positive            1                            9            16           26
   negative            10                           28           27           65
   p value             reference                    0.416        0.143        
  Mitoses/10HPF                                                               
   Mean (range)        14 (6-36)                    31 (6-108)   48 (6-118)   
   p value             reference                    0.001\*      \<0.001\*    

Discussion {#sec1-4}
==========

The present study reported the histopathological characteristics of Myanmar breast cancer patients. We analyzed 91 cases, in which 93% of the breast cancers were larger than 2 cm. There was no histological grade I and 53.8% of the cancers were grade III. Over half of the patients (57.1%) had lymph node involvement at the time of diagnosis. These findings may result from the lack of early detection system in Myanmar. It is also possible that Myanmar breast cancers are aggressive in nature.

Revealing the hormonal receptor status and HER2 and Ki-67 expression is useful not only for treatment strategy but for estimating the patient prognosis (malignant potential) (Goldhirsch et al., 2011). Generally, overall survival of breast cancers by subtypes from good- to poor-prognosis is: luminal A, luminal B, HER2 and TN (Hennigs et al., 2016). ER positive breast cancers are most frequent in western countries. In the United States, most (73%) breast cancers are luminal A and luminal B (HER2-) subtypes. About 10% of breast cancers are luminal B (HER2+), 4% are HER2 and 12% are TN (Howlader et al., 2014). [Table 4](#T4){ref-type="table"} shows the summary of the percent composition of molecular subtypes of breast cancers in western countries, South Asia, South-east Asia and East Asia. In Asian countries except China, HER2 and TN subtypes are prevailing compared to those in western countries. In the present Myanmar study, unfavorable molecular subtypes, HER2 and TN, were responsible for 42.9% of all cancers, suggesting that most breast cancers in Myanmar are aggressive in nature. Interestingly, the composition of molecular subtypes in Myanmar (this study) is comparable to that in a Vietnamese study (Thang et al., 2015), with low luminal A and B and in contrast high HER2 and TN. These similarities may be related to some genetic or biological connections, as well as comparable environmental factors.

###### 

Percent Composition of Molecular Subtypes of Breast Cancer in Different Countries

                  Luminal A   Luminal B (%)   HER2   TN     Number of cases   reference   
  --------------- ----------- --------------- ------ ------ ----------------- ----------- -----------------------------
  United States   (72.7       )               10.3   4.6    12.2              50,571      Howlader et al., 2014
  Italy           34.0        25.0            11.0   10.2   19.0              1,487       Caldarella et al., 2013
  Germany         44.7        31.8            6.2    5.0    12.3              3,454       Hennigs et al., 2016
  Australia       29.0        37.0            14.0   4.6    16.0              285         Mandaliya et al., 2016
  India           (53.3       )               10.1   13.0   23.8              1,284       Doval et al., 2015
  China           (65.3       )               19.0   6.5    9.2               3,198       Zhu et al., 2014
  Japan           30.6        26.2            19.0   11.3   12.9              363         Yanagawa et al., 2012
  Indonesia       38.1        (16.7           )      20.2   25.0              84          Widodo et al., 2014
  Malaysia        (48.0       )               12.0   11.0   29.0              1,034       Devi et al., 2012
  Thailand        39.0        8.0             10.0   18.0   25.0              100         Chuangsuwanich et al., 2014
  Vietnam         10.6        33.5            23.0   19.3   13.6              237         Thang et al., 2015
  Myanmar         11.0        39.6            6.6    22.0   20.9              91          Present study

In conclusion, the present study for the first time highlights the clinicopathological features of breast cancers from Myanmar women, which provide valuable information for the breast cancer control. Approximately 80% of the breast cancers were positive for either hormone receptor or HER2. Hormone therapy and anti-HER2 therapy may offer significant benefits to the Myanmar breast cancer patients, when used properly. Moreover, it is essential to establish early detection of breast cancer: education to promote early diagnosis and screening. Early detection alleviates the advanced breast cancer and increases the opportunities for successful treatment.
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